Area patients now have access to this next-generation BPH treatment providing clinically-proven, immediate and lasting results. Dr. Colin Ryan (center) is the physician who performed the procedure.
Central Ohio Urology Group announced today that it is the first in the Columbus, Ohio area to offer patients the Optilume® BPH Catheter System for the treatment of Benign Prostatic Hyperplasia (BPH). Typically administered as an outpatient procedure, Optilume BPH is a new, safe and effective minimally-invasive procedure that provides patients with immediate improvement in urinary symptoms and quality of life.
As men age, it’s common to encounter prostate enlargement, leading to a condition known as BPH. In fact, BPH affects 70% of men 60-69 years of age and 80% of those 70 years of age or older. The prostate surrounds the tube responsible for transporting urine and semen, know as the urethra. With BPH, as the prostate grows larger, it exerts pressure on the urethra, potentially causing interruptions in the natural flow of urine.
The FDA-approved Optilume BPH Catheter System revolutionizes the treatment paradigm by providing immediate and durable symptom relief for men experiencing BPH induced lower urinary tract symptoms, including frequent trips to the bathroom, day and night; weak, slow or intermittent flow; urgent need to pee; and inability to fully empty bladder.
Optilume BPH is a drug-coated balloon that is inserted into the urethra via a telescopic camera, to the prostate. Once in the prostate, the balloon expands creating an opening, and releases the safe and proven drug paclitaxel, into the open prostate. When the drug coating is fully released, the balloon is deflated and removed. The drug prevents re-fusion of the lobes during healing, keeping the prostate open, restoring the flow of urine and relieving bothersome BPH symptoms.
Highlights of the Optilume BPH Catheter System include:
- Clinical studies show Optilume BPH is safe and effective
- Immediate and durable symptom relief
- Minimal catheter time post-procedure
- No impact on sexual function
- Quick recovery
- Highest clinically reported flow rates of any minimal invasive therapy
- In-office/outpatient procedure
- No cutting, heating, burning, lasering, steaming, or implantation
Patients interested in a consultation with Dr. Colin Ryan can visit his bio page to schedule an appointment.
About Optilume BPH
The Optilume® BPH Catheter System, a new FDA-approved drug-coated balloon technology, provides a minimally invasive treatment option for men suffering from benign prostatic hyperplasia (BPH). The drug-coated balloon technology creates a paradigm change from methods currently used by urologists to treat these conditions. Optilume is owned by Laborie, a global medical technology company focused on Urology, Urogynecology, Gastroenterology, Obstetrics, Gynecology & Neonatal Health. For more information visit www.laborie.com or www.optilume.com/bph.